BBR Partners LLC Has $850,000 Position in 2seventy bio, Inc. (NASDAQ:TSVT)

BBR Partners LLC raised its position in 2seventy bio, Inc. (NASDAQ:TSVT) by 620.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 180,000 shares of the company’s stock after purchasing an additional 155,000 shares during the quarter. BBR Partners LLC owned 0.35% of 2seventy bio worth $850,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in TSVT. Marshall Wace LLP raised its holdings in 2seventy bio by 50.4% in the 2nd quarter. Marshall Wace LLP now owns 667,023 shares of the company’s stock valued at $2,568,000 after buying an additional 223,408 shares during the last quarter. Venator Management LLC raised its stake in shares of 2seventy bio by 49.2% during the second quarter. Venator Management LLC now owns 485,000 shares of the company’s stock valued at $1,867,000 after acquiring an additional 160,000 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in shares of 2seventy bio during the first quarter valued at $2,031,000. Bank of New York Mellon Corp lifted its holdings in shares of 2seventy bio by 5.4% during the second quarter. Bank of New York Mellon Corp now owns 196,959 shares of the company’s stock worth $758,000 after purchasing an additional 10,077 shares during the period. Finally, Susquehanna Fundamental Investments LLC grew its stake in shares of 2seventy bio by 39.1% in the second quarter. Susquehanna Fundamental Investments LLC now owns 192,319 shares of the company’s stock worth $740,000 after purchasing an additional 54,076 shares during the last quarter. 93.90% of the stock is owned by institutional investors and hedge funds.

2seventy bio Stock Up 7.3 %

NASDAQ TSVT opened at $3.96 on Thursday. The company has a market capitalization of $204.30 million, a price-to-earnings ratio of -2.15 and a beta of 1.78. 2seventy bio, Inc. has a twelve month low of $1.67 and a twelve month high of $6.40. The stock has a fifty day simple moving average of $4.55 and a 200 day simple moving average of $4.43.

2seventy bio Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.